Literature DB >> 15312305

Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin.

F Rahbarizadeh1, M J Rasaee, M Forouzandeh Moghadam, A A Allameh, E Sadroddiny.   

Abstract

Recently, the existence of "heavy-chain" antibody in Camelidae has been described. However, as yet there is no data on the binding of this type of antibody to peptides. In addition, there was not any report of production of single-domain antibodies in two-humped camels (Camelus bactrianus). In the present study, these questions are addressed. We showed the feasibility of immunizing old world camels, cloning the repertoire of the variable domain of their heavy-chain antibodies, panning and selection, leading to the successful identification of minimum-sized antigen binders. Antigen-specific fragments of the heavy-chain IgGs (V(HH)) are of great interest in biotechnology because they are very stable, highly soluble, and react specifically and with high affinity to the antigens. In this study, we immunized two camels (Camelus dromedarius and Camelus bactrianus) with homogenized cancerous tissues, synthetic peptide, and human milk fat globule membrane (HMFG), and generated two V(HH) libraries displayed on phage particles. Some single-domain antibody fragments have been isolated that specifically recognize the tandem repeat region of MUC1. The camels' single-domain V(HH) harbor the original, intact antigen binding site and reacted specifically and with high affinity to the tandem repeat region of MUC1. Indeed soluble, specific antigen binders and good affinities (in the range of 0.2 x 10(9) M(-1) to 0.6 x 10(9) M(-1)) were identified from these libraries. This is the first example of the isolation of camel anti-peptide V(HH) domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312305     DOI: 10.1089/1536859041224334

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  9 in total

Review 1.  A new generation of protein display scaffolds for molecular recognition.

Authors:  Ralf J Hosse; Achim Rothe; Barbara E Power
Journal:  Protein Sci       Date:  2006-01       Impact factor: 6.725

Review 2.  Production of recombinant antibodies using bacteriophages.

Authors:  A M Shukra; N V Sridevi
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-05-21

Review 3.  CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Med       Date:  2022-06-10       Impact factor: 9.927

Review 4.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

Review 5.  The Application of Nanobody in CAR-T Therapy.

Authors:  Chaolemeng Bao; Quanli Gao; Lin-Lin Li; Lu Han; Bingxiang Zhang; Yijin Ding; Zongpei Song; Ruining Zhang; Jishuai Zhang; Xian-Hui Wu
Journal:  Biomolecules       Date:  2021-02-08

6.  A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.

Authors:  Elmira Karami; Jean-Marc Sabatier; Mahdi Behdani; Shiva Irani; Fatemeh Kazemi-Lomedasht
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 7.  CAR-T cell potency: from structural elements to vector backbone components.

Authors:  Marzieh Mazinani; Fatemeh Rahbarizadeh
Journal:  Biomark Res       Date:  2022-09-19

8.  Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function.

Authors:  Fatemeh Kazemi-Lomedasht; Serge Muyldermans; Mahdi Habibi-Anbouhi; Mahdi Behdani
Journal:  Iran J Basic Med Sci       Date:  2018-03       Impact factor: 2.699

9.  Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors.

Authors:  Parnaz Merikhian; Behrad Darvishi; Neda Jalili; Mohammad Reza Esmailinejad; Azadeh Sharif Khatibi; Shima Moradi Kalbolandi; Malihe Salehi; Marjan Mosayebzadeh; Mahdieh Shokrollahi Barough; Keivan Majidzadeh-A; Fatemeh Yadegari; Fatemeh Rahbarizadeh; Leila Farahmand
Journal:  Mol Oncol       Date:  2021-11-19       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.